$1B+ deals) across a wide range of sectors, Adrienne's practice has a particular focus on the life sciences and health care, and technology industries and the overlap between them. Adrienne's transactional work has included experience with mergers, leveraged buyouts, tender offers, going-private transactions, de-SPAC acquisitions, carve-out and spin-off transactions and minority and growth investments.Adrienne's M&A practice is bolstered by Adrienne's strong experience in corporate governance matters. Adrienne routinely counsels boards and executive officers on their significant transactions, including fiduciary duty issues, and general corporate matters. Adrienne also regularly works with emerging growth companies on general corporate and financing matters.Prior to joining Hogan Lovells, Adrienne was previously the co-chair of a U.S.-based law firm's M&A and Private Equity Transactions Practices, co-lead of that firm's New York office, and a member of that firm's Diversity Committee. Adrienne also served rotations on that firm's Hiring Committee and Policy and Procedure Against Discrimination and Harassment Committee." /> $1B+ deals) across a wide range of sectors, Adrienne's practice has a particular focus on the life sciences and health care, and technology industries and the overlap between them. Adrienne's transactional work has included experience with mergers, leveraged buyouts, tender offers, going-private transactions, de-SPAC acquisitions, carve-out and spin-off transactions and minority and growth investments.Adrienne's M&A practice is bolstered by Adrienne's strong experience in corporate governance matters. Adrienne routinely counsels boards and executive officers on their significant transactions, including fiduciary duty issues, and general corporate matters. Adrienne also regularly works with emerging growth companies on general corporate and financing matters.Prior to joining Hogan Lovells, Adrienne was previously the co-chair of a U.S.-based law firm's M&A and Private Equity Transactions Practices, co-lead of that firm's New York office, and a member of that firm's Diversity Committee. Adrienne also served rotations on that firm's Hiring Committee and Policy and Procedure Against Discrimination and Harassment Committee." /> Adrienne Ellman | New York | Hogan Lovells

Adrienne Ellman

Partner Corporate & Finance

ellman-adrienne

Adrienne Ellman
ellman-adrienne
  • Overview
  • Experience
  • Credentials
  • Insights and events

Adrienne Ellman focuses on M&A and Private Equity transactions, representing corporate and financial buyers and sellers of public and private companies in domestic and cross-border transactions.

Recognized nationally as a "Leading Lawyer" in M&A by Legal 500 (>$1B+ deals) across a wide range of sectors, Adrienne's practice has a particular focus on the life sciences and health care, and technology industries and the overlap between them. Adrienne's transactional work has included experience with mergers, leveraged buyouts, tender offers, going-private transactions, de-SPAC acquisitions, carve-out and spin-off transactions and minority and growth investments.

Adrienne's M&A practice is bolstered by Adrienne's strong experience in corporate governance matters. Adrienne routinely counsels boards and executive officers on their significant transactions, including fiduciary duty issues, and general corporate matters. Adrienne also regularly works with emerging growth companies on general corporate and financing matters.

Prior to joining Hogan Lovells, Adrienne was previously the co-chair of a U.S.-based law firm's M&A and Private Equity Transactions Practices, co-lead of that firm's New York office, and a member of that firm's Diversity Committee. Adrienne also served rotations on that firm's Hiring Committee and Policy and Procedure Against Discrimination and Harassment Committee.

Representative experience

Equifax on its pending US$596m acquisition of Boa Vista Serviços in Brazil.

Thermo Fisher Scientific Inc. (NYSE: TMO) on its acquisition of MarqMetrix, Inc., a Seattle, Washington-based developer of Raman spectroscopy solutions.

indie Semiconductor (Nasdaq: INDI) on its acquisition of GEO Semiconductor Inc., a market leader in video processors for automotive cameras.

Thermo Fisher Scientific Inc. (NYSE: TMO) on its US$1.7bn acquisition of Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies.*

GreenLight Biosciences on a US$1.2bn SPAC business combination with Environmental Impact Acquisition Corp. (Nasdaq: ENVI), that resulted in GreenLight becoming a publicly listed company.*

Thermo Fisher Scientific (NYSE: TMO) on its US$1.85bn acquisition of PeproTech, a Cranbury, New Jersey-based provider of bioscience reagents.*

The PGA Corporation, a subsidiary of the PGA of America, on its acquisition of Nextgengolf to enhance player development programming designed to grow the game of golf across emerging generations.*

LevelUp, a leader in mobile diner engagement and payment solutions for restaurants, on its US$390m sale to online and mobile food-ordering and delivery marketplace Grubhub Inc.*

Thermo Fisher Scientific Inc. (NYSE: TMO), a global biotechnology company, on its US$477m acquisition of Becton, Dickinson and Company’s Advanced Bioprocessing business.

AurKa Pharma, Inc, a company established to develop an oncology compound with potential to treat certain types of solid tumors, on a sale worth up to US$575m to Eli Lilly and Company (Nasdaq: LLY).*

Inovalon Holdings Inc. (Nasdaq: INOV) on its US$1.2bn acquisition of ABILITY Network.*

Exa Corporation on its US$400m sale to French software company Dassault (EPA: DSY).*

IQuum, Inc. on its sale to Roche Molecular Systems, Inc. for approximately US$450m.*

Order Motion on its sale to NetSuite.*

deCODE Genetics ehf on its sale to Amgen Inc. (Nasdaq: AMGN) for approximately US$415m.*

The founders of Made4Net, LLC, a provider of warehouse management systems and supply chain execution software, and its foreign subsidiaries on the sale of shares to Thompson Street Capital Partners.*

Galen Partners, a healthcare-focused growth equity fund, on its acquisition of Evolve Treatment Centers, an adolescent behavioral health services provider.*

Mill Road Capital II, L.P. and its portfolio company, Skullcandy Inc., on the spin-off of Skullcandy’s ASTRO Gaming headset business to Logitech (Nasdaq: LOGI) for US$85m.*

Mill Road Capital on its tender offer for Skullcandy, Inc. for US$196.6m; its take-private of R.G. Barry Corporation for US$215m; and its take-private of Rubio’s Restaurants, Inc. for US$91m.*

Recorded Future, a security intelligence company, on its sale of a controlling interest in the company valued at more than US$780m to Insight Partners.*

*Matter handled prior to joining Hogan Lovells.

Credentials

Education
  • J.D., Northeastern University School of Law, 2009
  • B.A., Williams College, 2003
Bar admissions and qualifications
  • New York
  • Massachusetts

Recognition

Recognized nationally as a Leading Lawyer (>$1B Deals)

Legal 500

2023, 2024
Recognized nationally as a Leading Lawyer (Middle Market Deals)

Legal 500

2020-2022
Recognized nationally as a Next Generation Lawyer

Legal 500

2019